ERAS News

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting initial filings.   Italian drug container supplier Stevanato Group (STVN)...read more

Erasca, a Phase 2 biotech developing therapies for RAS/MAPK pathway-driven cancers, raised $300 million by offering 18.8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.3 million more shares than anticipated. Erasca employs a modality-agnostic approach to selectively and potently inhibit or degrade critical signaling nodes in the RAS/MAPK...read more

Erasca, a Phase 2 biotech developing therapies for RAS/MAPK pathway-driven cancers, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $263 million by offering 17.5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Erasca would command a fully diluted market value of $1.9 billion. Erasca employs a...read more

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900 million at a $6.8 billion market cap. Controlled by its founding family, the profitable company supplies glass vials,...read more